Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models.

Journal Article (Journal Article)

Adeno-associated virus (AAV)-mediated CRISPR-Cas9 editing holds promise to treat many diseases. The immune response to bacterial-derived Cas9 has been speculated as a hurdle for AAV-CRISPR therapy. However, immunological consequences of AAV-mediated Cas9 expression have thus far not been thoroughly investigated in large mammals. We evaluate Cas9-specific immune responses in canine models of Duchenne muscular dystrophy (DMD) following intramuscular and intravenous AAV-CRISPR therapy. Treatment results initially in robust dystrophin restoration in affected dogs but also induces muscle inflammation, and Cas9-specific humoral and cytotoxic T-lymphocyte (CTL) responses that are not prevented by the muscle-specific promoter and transient prednisolone immune suppression. In normal dogs, AAV-mediated Cas9 expression induces similar, though milder, immune responses. In contrast, other therapeutic (micro-dystrophin and SERCA2a) and reporter (alkaline phosphatase, AP) vectors result in persistent expression without inducing muscle inflammation. Our results suggest Cas9 immunity may represent a critical barrier for AAV-CRISPR therapy in large mammals.

Full Text

Duke Authors

Cited Authors

  • Hakim, CH; Kumar, SRP; Pérez-López, DO; Wasala, NB; Zhang, D; Yue, Y; Teixeira, J; Pan, X; Zhang, K; Million, ED; Nelson, CE; Metzger, S; Han, J; Louderman, JA; Schmidt, F; Feng, F; Grimm, D; Smith, BF; Yao, G; Yang, NN; Gersbach, CA; Chen, S-J; Herzog, RW; Duan, D

Published Date

  • November 2021

Published In

Volume / Issue

  • 12 / 1

Start / End Page

  • 6769 -

PubMed ID

  • 34819506

Pubmed Central ID

  • PMC8613397

Electronic International Standard Serial Number (EISSN)

  • 2041-1723

International Standard Serial Number (ISSN)

  • 2041-1723

Digital Object Identifier (DOI)

  • 10.1038/s41467-021-26830-7


  • eng